New insights into sex differences in primary biliary cholangitis. Gender difference in primary biliary cholangitis

被引:2
|
作者
Wu, Ying-Hsuen [1 ]
Chiu, Yi-Lin [2 ]
Lin, Jung-Chun [3 ]
Chen, Hsuan-Wei [3 ]
机构
[1] China Med Univ, China Med Univ Hosp, Coll Med, Sch Med,Dept Ophthalmol, Taichung, Taiwan
[2] Natl Def Med Ctr, Dept Biochem, Taipei, Taiwan
[3] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Taipei, Taiwan
关键词
Gender difference; Primary biliary cholangitis; Cholestasis;
D O I
10.47391/JPMA.01124
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To highlight the clinical characteristics of primary biliary cholangitis on the basis of gender in terms of the extent of liver injury and extra-liver autoimmune expressions. Methods: The retrospective study was conducted at the Tri-Service General Hospital, Taiwan, and comprised data of patients aged >20 years diagnosed with primary biliary cholangitis between January 2000 and December 2018. Patients in the control group were randomly selected from the health examination centre. Liver injury manifestations and susceptibilities were analysed along gender lines. The gene expression microarray data from the National Centre for Biotechnology Information Gene Expression Omnibus database was also used to explore the relationship between autoimmune-induced inflammation and androgen response expression. Statistical analysis was done using Graph-Pad Prism 7.0. Results: Of the 75 cases, 63(84%) were females with a mean age of 64.6 +/- 1.78 years, and 12(16%%) were males with a mean age of 46.6 +/- 5.6 years. Of the 66 controls, 55(83.3%) were females with a mean age of 51.67 years, and 11(16.6%) were males with a mean age of 45.9 years. There were no significant differences in terms of liver profiles related to gender in the control group (p>0.05). Among the cases, male patients showed fewer extrahepatic autoimmune disorders and more severe liver injuries before or after ursodeoxycholic acid treatment (p<0.05). There was a positive correlation between androgen receptor response and the extent of systemic inflammation (p<0.05). Conclusion:The association between androgen receptor responses and inflammation was linked to gender-related hepatic injuries, which may explain why liver inflammation in male patients is generally more severe compared to the female patients.
引用
收藏
页码:896 / 900
页数:5
相关论文
共 50 条
  • [21] Baricitinib and primary biliary cholangitis
    Gordon, Stuart C.
    Trudeau, Sheri
    Regev, Arie
    Uhas, Jonathan M.
    Chakladar, Sujatro
    Pinto-Correia, Ana
    Gottlieb, Klaus
    Schlichting, Doug
    JOURNAL OF TRANSLATIONAL AUTOIMMUNITY, 2021, 4
  • [22] Epigenetics of Primary Biliary Cholangitis
    Li, Yikang
    Tang, Ruqi
    Ma, Xiong
    EPIGENETICS IN ALLERGY AND AUTOIMMUNITY, 2020, 1253 : 259 - 283
  • [23] Genetics of Primary Biliary Cholangitis
    Gerussi, Alessio
    Asselta, Rosanna
    Invernizzi, Pietro
    CLINICS IN LIVER DISEASE, 2022, 26 (04) : 571 - 582
  • [24] Saroglitazar for primary biliary cholangitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (11): : 888 - 888
  • [25] Seladelpar for primary biliary cholangitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (05): : 414 - 414
  • [26] Osteoporosis in primary biliary cholangitis
    Christopher J Danford
    Hirsh D Trivedi
    Konstantinos Papamichael
    Elliot B Tapper
    Alan Bonder
    World Journal of Gastroenterology, 2018, 24 (31) : 3513 - 3520
  • [27] Bezafibrate in Primary Biliary Cholangitis
    Jones, David E.
    Hegade, Vinod S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (10): : 984 - 984
  • [28] Seladelpar for primary biliary cholangitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (06): : 510 - 510
  • [29] The genetics of primary biliary cholangitis
    Tanaka, Atsushi
    Leung, Patrick S. C.
    Gershwin, Merrill Eric
    CURRENT OPINION IN GASTROENTEROLOGY, 2019, 35 (02) : 93 - 98
  • [30] Autoantibodies in Primary Biliary Cholangitis
    Leung, Kristel K.
    Hirschfield, Gideon M.
    CLINICS IN LIVER DISEASE, 2022, 26 (04) : 613 - 627